Quarterly report pursuant to Section 13 or 15(d)

ACQUISITION (Details 1)

v3.8.0.1
ACQUISITION (Details 1) - Share Exchange Agreement [Member] - Lewis & Clark Pharmaceuticals, Inc. [Member] - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Revenue
Net loss $ (6,179) $ (2,828)
Net loss per share (in dollars per share) $ (0.71) $ (0.33)